新型冠状病毒SARS-CoV-2的相关研究——过去与未来
收稿日期: 2023-05-06
网络出版日期: 2023-09-01
张会 , 丁东瑞 , 金天然 . 新型冠状病毒SARS-CoV-2的相关研究——过去与未来[J]. 临床荟萃, 2023 , 38(7) : 638 -646 . DOI: 10.3969/j.issn.1004-583X.2023.07.010
| [1] | Cassandra A, Insha M, Robert M, et al. A Guide to COVID-19: A global pandemic caused by the novel coronavirus SARS-CoV-2[J]. FEBS J, 2020, 287(17): 3633-3650. |
| [2] | Li Q, Guan X, Wa P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020, 382(13): 1199-1207. |
| [3] | Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2[J]. Nat Microbiol, 2020, 5(4): 536-544. |
| [4] | Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273. |
| [5] | Vabret A, Mourez T, Dina J, et al. Human coronavirus NL63, France[J]. Emerg Infect Dis, 2005, 11(8): 1225-1229. |
| [6] | Kahn JS, McIntosh K. History and recent advances in coronavirus discovery[J]. Pediatr Infect Dis J, 2005, 24(11 Suppl): S223-S227. |
| [7] | Siddell SG, Anderson R, Cavanagh D, et al. Coronaviridae[J]. Intervirology, 1983, 20(4): 181-189. |
| [8] | Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses[J]. Trends Microbiol, 2016, 24(6): 490-502. |
| [9] | Sharma A, Ahmad FL, Lal SK. COVID-19: A review on the novel coronavirus disease evolution, transmission, detection, control and prevention[J]. Viruses, 2021, 13(2): 202. |
| [10] | Masters PS. The molecular biology of coronaviruses[J]. Adv Virus Res, 2006, 66: 193-292. |
| [11] | Wevers BA, van der HL. Recently discovered human coronaviruses[J]. Clin Lab Med, 2009, 29(4): 715-724. |
| [12] | Gaunt ER, Hardie A, Claas ECJ, et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method[J]. J Clin Microbiol, 2010, 48(8): 2940-2947. |
| [13] | Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19) outbreak-an update on the status[J]. Mil Med Res, 2020, 7(1): 11. |
| [14] | Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2[J]. Natl Sci Rev, 2020, 7(6): 1012-1213. |
| [15] | Delamater PL, Street EJ, Leslie TF, et al. Complexity of the basic reproduction number(R0)[J]. Emerg Infect Dis, 2019, 25(1): 1-4. |
| [16] | Killerby ME, Biggs HM, Midgley CM, et al. Middle east respiratory syndrome coronavirus transmission[J]. Emerg Infect Dis, 2020, 26(2): 191-198. |
| [17] | Riou J, Althaus CL. Pattern of early humanto-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020[J]. Euro surveill, 2020, 25(4): 2000058. |
| [18] | Zou L, Ruan F, Huang M, et al. SARSCoV-2 viral load in upper respiratory specimens of infected patients[J]. N Engl J Med, 2020, 382(12): 1177-1179. |
| [19] | Poltronieri P, Sun B, Mallardo M. RNA viruses: RNA roles in pathogenesis, coreplication and viral load[J]. Curr Genomics, 2015, 16(5): 327-335. |
| [20] | Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis[J]. Methods Mol Biol, 2015, 1282: 1-23. |
| [21] | Frieman M, Baric R. Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation[J]. Microbiol Mol Biol Rev, 2008, 72(4): 672-685. |
| [22] | Astuti I, Ysrafil. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response[J]. Diabetes Metab Syndr, 2020, 14(4): 407-412. |
| [23] | Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281-292. |
| [24] | Yan R, Zhang Y, Li Y, et al. Structural basis for the recognition of SARSCoV-2 by full-length human ACE2[J]. Science, 2020, 367(6485): 1444-1448. |
| [25] | Xia S, Liu M, Wang C, et al. Inhibition of SARS-CoV-2(previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion[J]. Cell Res, 2020, 30(4): 343-355. |
| [26] | Gao J, Lu G, Qi J, et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus[J]. J Virol, 2013, 87(24): 13134-13140. |
| [27] | Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483): 1260-1263. |
| [28] | He J, Tao H, Yan Y, et al. Molecular mechanism of evolution and human infection with SARS-CoV-2[J]. Viruses, 2020, 12(4): 428. |
| [29] | Wu Y, Long Y, Wang F, et al. Emergence of SARS-CoV-2 Omicron variant and strategies for tackling the infection[J]. Immun Inflamm Dis, 2022, 10(12): e733. |
| [30] | Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak[J]. J Autoimmun, 2020, 109: 102433. |
| [31] | Hosseini ES, Kashani NR, Nikzad H, et al. The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies[J]. Virology, 2020, 551: 1-9. |
| [32] | Garg S, Kim L, Whiteker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 states, March 1-30, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(15): 458-464. |
| [33] | Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: A model-based analysis[J]. Lancet Infect Dis, 2020, 20(6): 669-677. |
| [34] | 陈炎添, 郭翼华, 苏雪棠. 新型冠状病毒病暴发流行的个人防控[J]. 临床荟萃, 2020, 35(2): 101-105. |
| [35] | 尚伟锋, 李维, 周登峰. 新型冠状病毒肺炎临床特征的 Meta分析[J]. 临床荟萃, 2020, 35(4): 293-296. |
| [36] | 刘自强, 缪锦峰, 邹琼, 等. 新型冠状病毒肺炎患者发生复合终点事件危险因素的 Meta分析[J]. 临床荟萃, 2020, 35(9): 773-782. |
| [37] | Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5): 475-481. |
| [38] | Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy[J]. JAMA, 2020, 323(18): 1775-1776. |
| [39] | Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis[J]. Int J Infect Dis, 2016, 49: 129-133. |
| [40] | Channappannavar R, Fett C, Mack M, et al. Sex-based differences in susceptibility to severe acute respiratory syndrome coronaviruse infection[J]. J Immunol, 2017, 198(10): 4046-4053. |
| [41] | Dorn AV, Cooney RE, Sabin ML. COVID19 exacerbating inequalities in the US[J]. Lancet, 2020, 395(10232): 1243-1244. |
| [42] | Ather A, Patel B, Ruparel NB, et al. Coronavirus disease 19 (COVID-19): Implications for clinical dental care[J]. J Endod, 2020, 46(5): 584-595. |
| [43] | van DN, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1[J]. N Engl J Med, 2020, 382(16): 1564-1567. |
| [44] | Cai J, Sun W, Huang J, et al. Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020[J]. Emerg Infect Dis, 2020, 26(6): 1343-1345. |
| [45] | Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia[J]. J Med Virol, 2020, 92(6): 680-682. |
| [46] | Chen L, Lou J, Bai Y, et al. COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests[J]. Am J Gastroenterol, 2020, 115(5): 790. |
| [47] | Cheung KS, Hung IF, Chan PP, et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort: systematic review and meta-analysis[J]. Gastroenterology, 2020, 159(1): 81-95. |
| [48] | Drosten C, Meyer B, Müller MA, et al. Transmission of MERS-coronavirus in household contacts[J]. N Engl J Med, 2014, 371(9): 828-835. |
| [49] | Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study[J]. Lancet, 2020, 395(10223): 507-513. |
| [50] | Hui DS, Azhar EL, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China[J]. Int J Infect Dis, 2020, 91: 264-266. |
| [51] | 邹语嫣, 冯平勇, 梁康宁, 等. 64例新型冠状病毒肺炎患者的 CT 影像学特征分析[J]. 临床荟萃, 2020, 35(10): 880-884. |
| [52] | 张岩, 南成睿, 刘海霞, 等. 新型冠状病毒肺炎 CT 征象再讨论[J]. 临床荟萃, 2020, 35(2): 106-112. |
| [53] | Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. |
| [54] | Moxley G, Posthuma D, Carlson P, et al. Sexual dimorphism in innate immunity[J]. Arthritis Rheum, 2002, 46(1): 250-258. |
| [55] | Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 579(7798): 270-273. |
| [56] | Guan WJ, Zhong NS. Clinical characteristics of 2019 novel coronavirus infection in China reply[J]. N Engl J Med, 2020, 382(19): 1861-1862. |
| [57] | Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-A focused review for clinicians[J]. Clin Microbiol Infect, 2020, 26(7): 842-847. |
| [58] | Bridge JA. Reverse transcription-polymerase chain reaction molecular testing of cytology specimens: Pre-analytic and analytic factors[J]. Cancer Cytopathol, 2017, 125(1): 11-19. |
| [59] | Wong SCY, Kwong RTS, Wu TC, et al. Risk of nosocomial transmission of coronavirus disease 2019: An experience in a general ward setting in Hong Kong[J]. J Hosp Infect, 2020, 105(2): 119-127. |
| [60] | Konrad R, Eberle U, Dangel A, et al. Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020[J]. Euro Surveill, 2020, 25(9): 2000173. |
| [61] | Lorusso A, Calistri P, Mercante MT, et al. A “One-Health” approach for diagnosis and molecular characterization of SARS-CoV-2 in Italy[J]. One Health, 2020, 10: 100135. |
| [62] | Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential[J]. Biotechniques, 1999, 26(1): 112-125. |
| [63] | Romsos EL, Vallone PM. Rapid PCR of STR markers: applications to human identification[J]. Forensic Sci Int Genet, 2015, 18: 90-99. |
| [64] | Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results[J]. Expert Rev Mol Diagn, 2020, 20(5): 453-454. |
| [65] | Xia T, Li J, Gao J, et al. Small solitary ground-glass nodule on CT as an initial manifestation of coronavirus disease 2019 (COVID-19) pneumonia[J]. Korean J Radiol, 2020, 21(5): 545-549. |
| [66] | Moore NM, Li H, Schejbal D, et al. Comparison of two commercial molecular tests and a laboratory-developed modification of the CDC 2019- nCOV Reverse Transcriptase PCR assay for the qualitative detection of SARS-CoV-2[J]. J Clin Microbiol, 2020, 58(8): e00938. |
| [67] | Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523. |
| [68] | Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR[J]. Euro Survell, 2020, 25(3): 2000045. |
| [69] | Lei J, Li J, Li X, et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia[J]. Radiology, 2020, 295(1): 18. |
| [70] | Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: Comparison to RT-PCR[J]. Radiology, 2020, 296(2): E115-E117. |
| [71] | Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option[J]. Lancet, 2020, 395(10224): e35-e36. |
| [72] | Li G, Fan Y, Lai Y, et al. Coronavirus infections and immune responses[J]. J Med Virol, 2020, 92(4): 424-432. |
| [73] | Raeisossadati MJ, Danesh NM, Borna F, et al. Lateral flow based immunobiosensors for detection of food contaminants[J]. Biosens Bioelectron, 2016, 86: 235-246. |
| [74] | Infantino M, Damiani A, Gobbi FL, et al. Serological assays for SARSCoV-2 infectious disease: benefits, limitations and perspectives[J]. Isr Med Assoc J, 2020, 22(4): 203-210. |
| [75] | Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2[J]. Nat Biotechnol, 2020, 38(7): 807-874. |
| [76] | Chen JS, Ma E, Harrington LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity[J]. Science, 2018, 360(6387): 436-439. |
| [77] | Sahin AR, Erdogan A, Agaoglu PM, et al. Novel coronavirus (COVID-19) outbreak: a review of the current literature[J]. EJMO, 2020, 4(1): 1-7. |
| [78] | Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area[J]. JAMA, 2020, 323(20): 2052-2059. |
| [79] | Kupferschmidt K, Cohen J. Race to find COVID-19 treatments acceleratesi[J]. Science, 2020, 367(6485): 1412-1413. |
| [80] | Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020, 30(3): 269-271. |
| [81] | Tchesnokov EP, Feng JY, Porter DP, et al.(2019) Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by remdesivir[J]. Viruses, 2019, 11(4): 326. |
| [82] | Cao B, Wang Y, Wen D, et al. (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19[J]. N Engl J Med, 2020, 382(19): 1787-1799. |
| [83] | Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection[J]. Drugs, 2003, 63(8): 769-802. |
| [84] | Ronnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease[J]. Lupus Sci Med, 2019, 6(1): e000270. |
| [85] | Sallard E, Lescure FX, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19[J]. Antiviral Res, 2020, 178: 104791. |
| [86] | Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Res, 2020, 30(3): 269-271. |
| [87] | Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J]. Biosci Trends, 2020, 14(1): 72-73. |
| [88] | Tchesnokov EP, Feng JY, Porter DP, et al. Mechanism of inhibition of ebola virus RNAdependent RNA polymerase by remdesivir[J]. Viruses, 2019, 11(4): 326. |
| [89] | Ito K, Ohmagari N, Mikami A, et al. Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan[J]. Glob Health Med, 2020, 2(2): 96-101. |
| [90] | Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. Nat Commun, 2020, 11(1): 222. |
| [91] | Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: Host-directed therapies should be an option[J]. Lancet, 2020, 395(10224): e35-e36. |
| [92] | Abbott TR, Dhamdhere G, Liu Y, et al. Development of CRISPR as antiviral strategy to combat novel coronavirus and influenza[J]. Cell, 2020, 181(4): 865-876. |
| [93] | O’Connell MR. Molecular mechanisms of RNA targeting by Cas13-containing type VI CRISPR-Cas systems[J]. J Mol Biol, 2019, 431(1): 66-87. |
| [94] | To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study[J]. Lancet Infect Dis, 2020, 20(5): 565-574. |
| [95] | Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection[J]. Nat Commun, 2020, 11(1):2251. |
| [96] | Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab[J]. Proc Natl Acad Sci USA, 2020, 117(20): 10970-10975. |
| [97] | Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study[J]. Lancet Rheumatol, 2020, 2(8): e474-e484. |
| [98] | Kapadia SU, Rose JK, Lamirande E, et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine[J]. Virology, 2005, 340(2): 174-182. |
| [99] | Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic[J]. Asian Pac J Allergy Immunol, 2020, 38(1): 1-9. |
| [100] | He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: Implication for developing subunit vaccine[J]. Biochem Biophys Res Commun, 2004, 324(2): 773-781. |
| [101] | Brave A, Ljungberg K, Wahren B, et al. Vaccine delivery methods using viral vectors[J]. Mol Pharm, 2007, 4(1): 18-32. |
| [102] | Callaway E. Why does the Omicron sub-variant spread faster than the original?[J]. Nature, 2022, 602(7898): 556-557. |
| [103] | Adam D. Will Omicron end the pandemic? Here's what experts say[J]. Nature, 2022, 602(7895): 20-21. |
| [104] | Du Z, Hong H, Wang S, et al. Reproduction number of the Omicron variant triples that of the Delta variant[J]. Viruses, 2022, 14(4): 821. |
| [105] | Liu Y, Rocklov J. The effective reproduction number for the omicron variant of SARS-CoV-2 is several times relative to Delta[J]. J Travel Med, 2022, 29(3): taac037. |
| [106] | Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID study[J]. Lancet, 2022, 399(10335): 1618-1624. |
| [107] | Kristine AM, Tabitha L, Julia TO, et al. A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy[J]. Vaccine, 2023, 41(13): 2101-2112. |
| [108] | Grewal R, Kitchen SA, Nguyen L, et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the omicron variant among long term care residents in Ontario, Canada: test negative design study[J]. BMJ, 2022, 378: e071502. |
| [109] | Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study[J]. Lancet, 2021, 398(10316): 2093-2100. |
| [110] | Nordstrom P, Ballin M, Nordstrom A. Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: a nationwide, retrospective cohort study in Sweden[J]. Lancet Reg Health Eur, 2022, 21: 100466. |
| [111] | Heather LW, Cassandra MB, Isamara NM, et al. The coronavirus recombination pathway[J]. Cell Host Microbe, 2023, 31(6): 874-889. |
| [112] | Yang CP, Chang CM, Yang CC, et al. Long COVID and long chain fatty acids (LCFAs): Psychoneuro immunity implication of omega-3 LCFAs in delayed consequences of COVID-19[J]. Brain Behav Immun, 2022, 103: 19-27. |
/
| 〈 |
|
〉 |